Design: Patients trialled HumaPen Ergo ® (Eli Lilly) over 5 to 7 weeks and completed a questionnaire at the conclusion of the study.

At entry to the study 43 patients (61%) were using Novopen ® 3 to administer their insulin, 22 (31%) were using syringes, and five (7%) had used a combination of Novopen ® 3 and syringes.